The alteration of the SLC13A5 expression and function in these tissues is closely associated with obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), inflammation, cancer, and neurological disorders. The gene discussed is SLC13A5; the disease is metabolic dysfunction-associated steatotic liver disease.